Qiagen N.V. (NYSE:QGEN) Q4 2023 Earnings Call Transcript

Qiagen N.V. (NYSE:QGEN) Q4 2023 Earnings Call Transcript February 11, 2024

Qiagen N.V. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good day. I’m Melinda, your PGI call operator. Welcome, and thank you for joining Qiagen’s Fourth Quarter 2023 Earnings Conference Call Webcast. [Operator Instructions] Please be advised that this call is being recorded at QIAGEN’s request and will be made available on their Internet site. The prepared remarks will be followed by a question-and-answer session. [Operator Instructions] At this time, I’d like to introduce your host, John Gilardi, Vice President, Head of Corporate Communications and Investor Relations at QIAGEN. Please go ahead.

John Gilardi: Thank you, operator, and a welcome to all of you today who are joining us for this call. We appreciate your interest in QIAGEN. Our speakers are Thierry Bernard, our Chief Executive Officer, and Roland Sackers, our Chief Financial Officer. We also have Phoebe Loh from the IR team with us. This call is being webcast live and will be archived on the investors section of our website at www.qiagen.com. You can also find a copy of the quarterly results press release and presentation on our website. We will begin with some remarks from Thierry and Roland, followed by a Q&A session. Before we start, let me note that we are going to have an Analyst and Investor Day on Monday, June 17 in New York. An invitation to the event will be going out in the next few weeks, but please mark this in your calendars.

And also before we start, let’s briefly go over our safe harbor statement. The views expressed during this conference call and the responses to your questions represent the perspectives of management as of today, February 7, 2024. We will be making statements and providing responses to your questions that convey our intentions, beliefs, expectations or predictions for the future. These forward-looking statements fall under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. They involve risks and uncertainties, and actual results may differ materially from those suggested by these forward-looking statements. Factors that could influence results are mentioned in our filings with the U.S. Securities and Exchange Commission.

These filings are available on the SEC’s website and also on our website. QIAGEN disclaims any intention or obligation to update any forward-looking statements. Additionally, we will refer to certain financial measures not prepared following Generally Accepted Accounting Principles or GAAP. All references to EPS refer to diluted EPS. You can find a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measure in our press release and presentation. Now I would like to hand over the call to Thierry.

Thierry Bernard: Thank you, John. Hello and good morning, good afternoon or good evening depending on where you are in the world and thank you once again for joining us. Thank you for your continuous interest in our company, QIAGEN. We continue today reporting another solid year, and a strong performance in the fourth quarter. Amid the dynamic macro-environment, our teams continued to execute, delivering solid sales and installed base growth. This is a further testament to how our strategy of balance and focus has positioned our portfolios well to expand our leadership in both Life Sciences and Molecular Diagnostics. Let me go through the key messages for today as we dive into the details: First, we exceeded our outlook for net sales and adjusted EPS for the fourth quarter and achieved our full-year outlook.

Net sales for the fourth quarter were $ 503 million at CER, which exceeded our outlook for at least $ 500 million. Our non-COVID base business delivered one of the top performances in the industry with 8% CER sales growth over the prior year fourth quarter. This was driven by ongoing strong demand for consumables that accounted for over 85% of total sales. Net sales for the full year were [$9.97] (SEC) [$1.97] billion at CER, and this was on point for our sales outlook for 2023. Our non-COVID sales also grew 8% CER for the year compared to the year 2022. Adjusted earnings per share for the fourth quarter were $0.55 CER, above the outlook for at least $0.53 CER. For the full year, adjusted diluted EPS were $2.09 CER and above the outlook for at least $2.07 CER.

Our second key message. Our teams executed well to deliver growth and build value in our portfolio, achieving some important milestones in our pillars of growth. First, Sample Technologies capped the year with 6% CER growth in non-COVID related sales and over 1,500 new automation system placed in the market in 2023. The QuantiFERON latent TB test reached more than $400 million of annual sales for the first time and also had 3 consecutive quarters of sales above $100 million during the year. The QIAstat-Dx syndromic testing platform grew 7% CER in non-COVID sales for the full year 2023 and passed several key milestones. Over 1 million cartridges of QIAstat were shipped in 2023 and driven by double-digit CER sales growth outside the U.S. Globally, full year sales of meningitis and GI, our gastrointestinal panel doubled compared to 2022.

In addition, the fourth quarter saw the highest number of quarterly placement for the year and bringing the total number of cumulative placement to over 4,000 systems. The QIAcuity digital PCR system also performed well, delivering double-digit full year sales growth at constant exchange rates and met the milestone of over 2,000 cumulative plasma. Our third message, we again delivered a high level of profitability as we remain dedicated to investing into research and development. The adjusted operating income margin rose to 28% in the fourth quarter even as we continue to invest in expanding menus and driving innovation in our portfolio with about 9% of our sales going into research and development. And our last point, we have initiated full year ’24 outlook taking into account the volatile macro environment against the solid trends of our non-COVID business.

For 2024, we have set an outlook for at least $2 billion of sales at CER and for adjusted EPS of at least $2.10 CER again. Roland will give you more details on our outlook assumptions later in the call. Before I hand over to Roland, I would like to welcome our 2 new members to our Supervisory Board. In March, Eva van Pelt will be joining the Board, bringing with her an extensive experience in our industry. Most recently, Eva served as Co-CEO of Eppendorf, a privately held German Life Science Company and before held previous position with Siemens, Accenture, Hitachi Data Systems and Leica Microsystem. A month later in April, Bert van Meurs will also be joining the Board. Bert is currently a member of the Executive Committee at Royal Philips N.V. in the Netherlands, where he’s leading their image-guided therapy business as well as the precision diagnosis business.

We are pleased to have Bert’s industry experience, but also his knowledge of operating in the Netherlands. They both will be a very valuable addition to our diverse board, and we are looking forward to their contribution. Now I would like to hand over to Roland for a review of our results.

Roland Sackers: Thank you, Thierry. Hello, everyone. Thank you as well from me for joining our call. Let me first discuss our results for the fourth quarter and the full year and then share some views on our outlook for 2024. As you saw in our press release, net sales for the fourth quarter of ’23 were $509 million, up 2% from the year ago period, even against a substantial decline in COVID-19 revenues. We saw modestly positive currency movements against U.S. dollar, so this helped sales at actual rates. Consumables and related revenues led the performance, rising 10% CER for non-COVID product groups. Sales of instruments declined 2% CER for the non-COVID product groups in the fourth quarter of ’23, a signal of the conservative spending environment for capital sales.

At the same time, we achieved some important milestones for placements, especially for QIAstat-Dx and QIAcuity as we continue to see good placement trends for reagent rental agreements with multiyear consumable contracts. Overall, sales for the full year showed a decline of 8% against ’22 reflecting the drop of in COVID-19 testing, while we delivered 8% CER growth in the non-COVID portfolio that represented over 90% of total sales in ’23. Looking at the non-COVID growth for the year at 8% CER. This included the strong performance from QuantiFERON, growing well above our target rate for at least 10% CER while also having to absorb the volatility in our OEM business. Taking out both of these factors, non-COVID sales were still up 7% CER in ’23 over ’22.

Among our 4 product groups, the first is Sample Technologies, and this represents about 1/3 of total sales. For the non-COVID products, this sales growth at a mid-single-digit CER rate for both Q4 ’23 and for full year over the same period in ’22. Our second product group Diagnostic Solutions also represents about 1/3 of sales and delivered mid-single-digit CER sales growth in ’23. Within this product group, the QuantiFERON TB test continued to capture growth from conversion of tuberculin skin testing to modern blood testing and finished an outstanding year with 24% CER growth of over ’22 and achieving more than $400 million for the first time. For the QIAstat-Dx system for syndromic testing, sales faced some headwinds from COVID-19 testing, but saw underlying non-COVID sales rising at a solid single-digit CER rate.

Results for NeuMoDx, our integrated clinical PCR testing platform also reflected the significant headwinds from the high level of revenues from COVID-19 testing in ’22. In the third group, which involves PCR Nucleic acid amplification products, sales declined 1% CER in the fourth quarter. This was much better than the overall trend during the year with sales for ’23 down more than 20% compared to ’22. As we have been mentioning, the reason for the sharp drop-off in these sales in ’23 has been the volatility in orders from our OEM third-party customers that use our reagents for their own products. An important driver in the PCR/ Nucleic acid product group is QIAcuity, our group of digital PCR platform. Here, we saw dynamic growth during ’23 as our teams exceeded the goal for at least $70 million of annual sales.

This growth was driven by increasing consumables pull-through along with new placements especially in the biopharma sector. Genomic NGS is our last product group. This includes our QIAGEN Digital Insights Bioinformatics business and the QIAseq consumables portfolio designed for use with any third-party next-generation sequencer. The QDI business had another solid performance in Q4 and for the full year, delivering double-digit CER growth in ’23 over ’22. In terms of sales on a geographic basis, the Americas delivered mid-single-digit CER growth in the fourth quarter of ’23 in terms of total sales with non-COVID product groups rising 9% CER over the fourth quarter of ’22. We also had a similar trend on a full year basis with sales for non-COVID products groups rising 10% CER over ’22 on the back of solid growth in QuantiFERON as well as the Life Science portfolio driven by QIAcuity.

The Europe, Middle East, Africa region grew at a double-digit CER pace for both the fourth quarter and the full year when excluding COVID-19 headwinds. In terms of COVID-19 sales, the top performing — in terms of non-COVID sales the top-performing countries for the fourth quarter included France, Germany, Italy and the United Kingdom. In the Asia Pacific, Japan region, Sales in the fourth quarter were also affected by COVID-19 headwinds from ’22. They were also modestly lower over the year ago period for the non-COVID product group as well. This was due to the double-digit CER sales decline in China where macro-driven demand was weaker than expected in the fourth quarter. For the full year, China sales declined at a low single-digit CER rate over ’22, but this was more than offset by higher sales in the rest of the region especially South Korea and India.

Let’s now review the rest of the income statement. For the fourth quarter, adjusted operating income rose 6% at $142 million from the fourth quarter of ’22, and we also generated higher operating income on a reported basis over the year ago period. This led to an adjusted operating income margin of 28% for the fourth quarter, up from 27.1% in the same period of ’22. We delivered this improvement despite the adjusted gross margin failing to 65.7% in the ’23 quarter, a decline of about 1.3 percentage points from the fourth quarter of ’22. This was due to an adverse change in product mix as well as low utilization levels for some manufacturing capacity that we have built up to support new product launches. We expect the gross margin to improve as we build up sales in these newer products.

In terms of R&D expenses, this remained at a high level at 9% of sales and unchanged from the fourth quarter of ’22. This was also in line with our ’23 goal for investments at 9% to 10% rate. Sales and marketing expenses benefited from improvement in greater focus on efficiency and customer engagement, especially through digital channels. These expenses were 23.1% of sales in the fourth quarter of ’23, down about 1.4 percentage points from last year. General and administrative expenses were also less than in the fourth quarter of ’22, falling to 5.6% of sales compared to 6.4% a year ago. For the full year, the adjusted operating income margin was 26.9% of sales compared to 30.6% in ’22, supporting against a high level of R&D investments while absorbing investments to commercialization.

We also faced a lower adjusted gross margin for the year at 66.4% of sales compared to 67.7% in ’22. And again, for the reasons outlined earlier. To close out the income statement, adjusted EPS for the fourth quarter was $0.55 at constant exchange rates and above the outlook or at least $0.53 CER. For the full year, adjusted EPS was $2.07 at actual rates, while results at constant exchange rates were $0.02 better at $2.09 due to some adverse currency trends against U.S. dollar on a full year basis. As we have mentioned earlier, a key factor in ’23 was the nonoperating income benefit to interest income due to the significant higher interest rate environment compared to ’22. Turning to cash flow, the 2023 reflects the lower levels of sales and net income compared to ’22 as we move beyond the pandemic.

Operating cash flow was $459 million for ’23 while free cash flow was $310 million. Beyond the impact of lower sales and profitability, we are in a period of higher working capital requirements. This is due to our decisions to maintain a relatively high level of inventories in light of the challenging geopolitical and macro environment. We want to ensure that QIAGEN can provide products to customers around the world without disruptions. This trend is also reflected in the ongoing high levels of inventories on the balance sheet. Continuing with the balance sheet, our liquidity position was about $1.1 billion at the end of ’23 and this compares to $1.4 billion at the end of ’22. Taking into consideration the recent synthetic share repurchase, which we returned about $300 million for QIAGEN shareholders.

Our leverage ratio would be about 1.1x net debt to EBITDA compared to 0.6x at the end of ’23 and 0.5x at the end of ’22. Keep in mind, for ’24 that we have about $600 million of debt reaching maturity and this builds on having repaid about $400 million of debt during ’23 from existing cash reserves. We are reviewing other ways to deploy cash within our disciplined allocation strategy, which has proved its value over the last decade. Given our healthy balance sheet and strong cash flows, we want to continue creating value by investing internally into the business as we see with our announcements about the multiyear investment in the QIAGEN Digital Insight business, as well as through targeted bolt-on acquisitions that complement our portfolio.

I would now like to hand back to Thierry.

Thierry Bernard: Thank you, Roland. And now, as usual, please allow me to take a moment to go over some of the progress our teams have made in advancing our portfolios. First of all, we continue to build on our leading position in sample technologies with portfolio expansion and installed base growth. It is where we have a clear focus on key growth areas such as microbiome and liquid biopsy. In those areas, our deep expertise give us significant differentiation. This quarter, as an example, we have again expanded our best-in-class microbiome portfolio with the launch of the RNeasy PowerMax Soil Pro Kit for isolating RNA from challenging soil samples rich in PCR inhibitors While you have heard companies in our industry talking about challenging trends in instrument demand, our teams all over the world have still made significant progress in the last year in placing new platforms.

At the end of 2023, there are now over 40,000 cumulative placement of the QIAcube family and over 5,700 cumulative placement of EZ1 and EZ2, both extremely popular solution for low throughput sample prep automation. For higher throughput, there are now over 3,300 cumulative placements of our flagship system, the QIAsymphony. The upgrade for this platform is in development and will include new onboard connectivity elements together with additional features to even better enable high-demand, high-volume application such as liquid biopsy. In our diagnostic portfolio, we continue to see strong global expansion of our products while also facilitating growth through partnerships. For example, you may have seen the recent announcement of our expansion in the Middle East.

This includes an agreement for the QuantiFERON latent TB testing to be used in Oman’s new screening program were over 800,000 people will be tested over a span of 2 years. This represents the healthy trends we are seeing in the increase of global latent TB testing and the conversion from the old skin test to the modern blood-based testing. We have also signed an agreement with the Ministry of Health in Saudi Arabia to support their public health and infection control initiatives. In addition to the development of the new national latent TB screening program using the QuantiFERON-TB test, this includes an effort to eliminate meningitis through the WHO program using QIAstat diagnostic platform. This represents another good example of how syndromic testing is being employed more and more to detect menangiitis.

In fact, we saw the highest quarterly sales yet for the QIAstat platform for meningitis in Q4 of 2023. Another example, through our companion diagnostic program QIAGEN and Myriad Genetics entered into a collaboration to provide next-generation sequencing and digital PCR solution to pharma companies for the development of cancer test. This adds to the over 30 active partnership we have with pharma companies, where we are one of the only companies to offer development of assays based on all 3 modalities. PCR next-generation sequencing and digital PCR. In PCR and nucleic acid amplification, we have launched new kits and software updates for QIAcuity digital PCR to expand capabilities in pharma, biopharma and food and drug safety. The new kits ensure precise quantification, increased sensitivity and cost efficiency for applications specifically used by these customers.

While the software update further equips QIAcuity to be especially well suited for labs that must meet GMP standard by helping to automate the critical task of documentation for reporting and audit trails. In our next-generation sequencing and genomics product group, we have recently entered into a new strategic partnership with Element Biosciences to offer NGS workflow on their AVITI System. This follows our strategy to offer platform-agnostic next-generation sequencing consumable and bioinformatics solution. In this way, QIAGEN has been systematically partnering with sequencing platform providers to enable the use of QIAGEN’s QIAseq library prep kits and validated panels as well as QIAGEN Digital Insight solution on a very large range of sequencing instruments.

With regards to our QDI, our bioinformatics business, we have made the decision to accelerate our own investments with the goal of expanding this leading portfolio into new geographic regions and market segments. This investment is planned over the next 5 years and will support new product launches and also additional expansion of the knowledge bases that are powering our QDI solutions. Also planning this program is the extension of the use of artificial intelligence and augmented molecular intelligence as well as new solutions for rapid NGS analysis in clinical labs. So as you can see, we continue to build value in our portfolio with a strategy that is leveraging our strong global footprint, deep network and innovation through expertise. And now back to Roland to give you more details on our outlook ’24.

Roland Sackers: Thank you, Thierry. Let me now provide more perspectives on our outlook for ’24 and also for the first quarter. As noted earlier, we have set an outlook for at least $2 billion of sales in ’24 at constant exchange rates. This reflects total growth at least 2% CER that includes about 1 percentage point of headwinds as we overcome the last group of COVID-19 sales from the first quarter of ’23. This means that we are expecting at least 3% CER growth from the non-COVID portfolio. In terms of how we see this year developing like others, we are anticipating a more muted start into the year with a return to solid mid-single-digit CER growth in the second half. Additionally, we have closely monitoring dynamic macro trends and geopolitical risk across the globe as to how they could impact our industry.

For China, we continue to take a cautious view and expect a modest single-digit CER decline in total sales for the full year. The environment is not showing any signs of improvement yet. At the same time, this is not a market to ignore. We continue to implement our two-pronged strategy by commercialization, the QIAGEN branded portfolio directly as well as offering a local brand product in China. As we take a step back from ’24, our conviction remains strong about the midterm growth perspective for QIAGEN in the markets that we serve. This is a topic we will address in our Analyst and Investor Day planned for June 17 in New York. In terms of profitability, we have set our outlook for adjusted EPS of at least $2.10 at constant exchange rates.

For the just operating income margin, we are planning for an improvement of at least 1 percentage point for the full year ’24 from the ’23 level of 27% of sales while continuing to invest in the business to support our business. This includes the investments into QDI business in ’24 as we plan to add more than 50 new positions. Launched the sales of new products and expand our global presence. We see these multiyear investments helping to accelerate growth in this profitable business. As we noted in the quarterly report, we anticipate significant pressure from nonoperating income, and these factors represent about $0.10 of headwind for ’24 results compared to ’23. First, adjusted net interest income is expected to be between $25 million and $27 million for ’24.

This is half the ’23 levels of $55 million. The decline is due to the fact that we have lower cash on our balance sheet, along with expectations for modestly lower interest rates during the year compared to ’23. The second factor involves our expectations for an adjusted tax rate for about 19% to 20% in ’24. This is up from 18% in ’23. The increase is due to higher profit shares in higher tax jurisdictions as well as countries taking actions to implement the OECD initiatives known as Pillar 2. The Netherlands implemented this at the end of ’23. As for currency movements and based on rates as of January 31, we expect a neutral impact on full year net sales, but for an adverse impact of about $0.01 per share on adjusted EPS results. Moving to the first quarter.

Our outlook is for net sales of about $455 million CER. Keep in mind that this will be a period with significant COVID sales in ’23. Adjusted earnings per share are expected to be at least $0.44 per share also at CER. I would like to now hand back to Thierry.

Thierry Bernard: Well, thank you, Roland. And we are getting now into the Q&A session. So let me provide you with a quick summary. First, amid the ongoing volatile macro environment, QIAGEN has delivered another quarter of meeting or beating our outlook. We exceeded our outlook for the fourth quarter for both net sales and adjusted EPS. We also achieved our full year 2023 sales outlook driven by top-tier growth in our non-COVID portfolio. Our performance in 2023 definitely shows the relevance and power of our portfolios of solutions to customers around the world and the impact of our strategy. Second, throughout 2023, our teams all over the world continue to execute on our goals to build value in our portfolio, meeting key milestones on sales growth and solid installed base expansion.

This includes over 1,500 sample preparation instruments. Over 700 QIAstat platform and over 700 QIAcuity newly placed in 2023, all fueling strong consumables growth going forward. Third, we again delivered a high level of profitability while also maintaining our commitment to disciplined capital deployment, as you saw with the ongoing high level of R&D research and development investment in 2023. The multiyear investment plan for our bioinformatics business and the $300 million recently returned to shareholders. And last, we have announced an outlook for 2024 that demonstrates the strength of our portfolio amid a challenging macroenvironment. While we fully acknowledge a shift in the first part of the year 2024, this takes into account the more subdued market demand in the first half given the current condition such as lack of visibility on funding and conservative spending in labs going into election year into many countries.

But we expect a marked improvement as the year unfolds as we return to a strong mid-single-digit CER sales growth for the second half of the year. We strongly believe that this sets up QIAGEN for solid midterm sales growth and improving profitability. We are, therefore, very well positioned to continue delivering a compelling growth profile in our industry. With that, I now would like to hand back to John and the operator for the Q&A session. Thank you all.

Operator: Ladies and gentlemen, at this time, we will begin the question-and-answer session. [Operator Instructions] The first question comes from Derik De Bruin of Bank of America. Please go ahead.

See also 12 Highest Quality Fried Chicken Chains In The US and Best Birth Injury Lawyers in Each of 30 Biggest Cities in the US.

Q&A Session

Derik De Bruin: Hi. Good morning. Thank you for taking my question. Just curious, can you elaborate a little bit more on the OEM headwind and sort of, like how you see that coming through for 2024 on what’s there. And I know you’re going to have an Analyst Day in June. But I think when you look at a more normalized market environment, do you feel comfortable in sort of, returning to mid- to high single-digit consistently CER growth rate once markets normalize on a more basis? Thank you.

Thierry Bernard: Thank you, Derek. Regarding, first, the OEM question. As you have always understood, this is a specific business in our portfolio. It’s made on very large deliveries, most of the time in bulk to a rather limited number of customers. So you have and we have always disclosed that to the market volatility year-on-year. The average revenue pre-COVID for our OEM business was around $80 million to $90 million. During COVID, it showed up to around $170 million. We are now getting back to normalization, but take into account that in 2023, we achieved close to $100 million with this business. So we expect in ’24 a headwind compared to our normal performance of around $15 million to $20 million. This should normalize as the year goes by.

Further, starting in ’25, you should expect that business coming back to normally $75 million, $80 million year-on-year. To your question of our growth profile, we believe that we are building systematically for the last 5 years, a stronger QIAGEN. We have the people. We have the product portfolio to systematically grow above market growth regardless of where that market growth is. So if the market is back to let’s say, mid-single-digit growth profile, we will be there, and we will be able to probably be slightly above that.

Operator: Our next question comes from Odysseas Manesiotis with Berenberg. Please go ahead.

Odysseas Manesiotis: Hi, thanks for taking my questions. First of all, this time last year, you mentioned you would be negotiating renewal terms with DSR and for your QuantiFERON partnership. Have these negotiations ended? And is it reasonable to assume you’ll be getting slightly better financial in terms of the results? And secondly, looking at the NeuMoDx guidance it seems you’re expecting this one to outgrow most of your growth pillars this year. Taking into account your commentary that instrument placements shouldn’t recover strongly in the near term. What will drive that significant consumables pull-through increase for these instruments. Thank you.

Thierry Bernard: Thank you, Odysseas. And going directly to the second part of your question, and then I will finish with QuantiFERON. On the NeuMoDx, it’s not that the percentage outgrow, yes, the percentage of growth is — but it’s starting from a lower base. We’re starting from slightly over 40 million, and we go over 50 million in our plan for 2024. Why? Because as you have seen, for example, we start to add menu in the U.S. You have seen the recent approval of our CT&G in addition to our capabilities on LDTs that gives a factor of growth. Second, because we already have something like 330 platforms all over the world. We have very significant menu availabilities in Europe, so we expect the pull-through on this installed base to grow.

And this is explaining our assumptions for NeuMoDx. But at the same time, as you know, Odysseas, we have disclosed to the market that we are currently reviewing any kind of evolution for this portfolio for the NeuMoDx within our portfolio. And we’ll come back to you in due time on the results of those evaluations. On DiaSorin, I think we need to clarify. What we said since 2023 is that starting 2023 in Europe, and ’24 in the U.S., QIAGEN has the possibility by contract to add another partner together with DiaSorin. The situation at the moment is that as we have proven with our members, this partnership and this exclusivity with DiaSorin works very well. Any time we convert a customer to DiaSorin, we are able to do it at a premium price. This partnership partially drives the performance that you have seen over the last 3 years for QuantiFERON.

So at the moment, while we always continue to review opportunities, we believe that this exclusivity is very justified and is generating positive results for both partners. As far as the financials, we constantly worked with DiaSorin to optimize the financials for both parties.

Odysseas Manesiotis: Very good. Thank you.

Operator: Our next question comes from Casey Woodring with JPMorgan. Please go ahead.

Casey Woodring: Great. Thank you for taking my questions. So I was hoping that you guys could dig into the 1Q guide a little bit more. Roland, I think you said in the prepared, you’re assuming conditions are softer in the first half versus the second half, but you just grew 8% non-COVID in 4Q. So does seem to be a bit off trend. Maybe can you just elaborate on maybe what you’re expecting as an OEM headwind in 1Q specifically? And then just as a follow-up, curious on QIAcuity, do you guys think you’re taking share there? And maybe can you split out the competitive share gains between pharma and academic if you’re seeing particular strength in pharma or if it’s more across the board? Thank you.

Roland Sackers: Yes, Casey, a couple of facts here. And I think we clearly cited and you have heard that from many other companies in our industry as well, the overall macro environment in general. But clearly, Pacific also a couple of trends which we have seen also more or less falling up in the last couple of weeks/months, it’s quite obvious, but for capital expenditures, particular for the bigger ticket environment. Things right now are more difficult. We clearly see a certain increased demand for reagent rentals, where the capital sales environment is clearly somewhat more difficult. As I said before, we believe that is something that is rather more on the temporary side, and we expect to return to a more solid mid-single-digit trend over the course of the year.

Nevertheless, it is not an easy environment. Specifically, in OEM, I think we are somewhat down in the high single-digit area. I think some of the $8 million and $10 million in the first quarter compared to the rest — compared to ’23. Nevertheless, it’s also important to understand, and I actually looked it up now for the years 2016 to actually including 2019, so more or less four years pre-COVID, the drop in absolute revenues between the fourth quarter and the first quarter was always around about $50 million plus. So not very different.

Operator: Our next question comes from Aisyah Noor of Morgan Stanley. Please go ahead.

Aisyah Noor: Hello, Thierry and Roland. Thanks for taking my questions.

Thierry Bernard: Hold on. Hold on. I’m sorry, I need to interrupt you. We’re going to get back to your question. There was a second half of the question, which was on QIAcuity, which we did not answer yet. So I’m going to take that one, and we go back immediately to your question. Is that okay?

Aisyah Noor: Sure.

Thierry Bernard: Very good. Thank you. So on QIAcuity, yes, we do obviously can see show with our numbers that we are taking share, and we are taking market shares of our competition. Why? First of all, because our technology different from the traditional droplet technologies is more cost efficient and allows faster results. Second, because if you remember, we cover with 3 different instruments, 3 kind of different throughput needs. Low throughput, one plate; mid throughput, 4 plates; 8 throughput, larger plates. 4, 3 sorry because we have already developed a menu which is covering application needed in academia, but also in the pharmacy also the pharma business sector. This is definitely our target, main target for the months to come.

And this is why you have seen a constant improvement of our digital PCR menu over the last 2 years, dedicated to the Pharma segment. And fourth, why do we believe so much into our digital PCR solution for the coming years as well is that not only can we leverage the growth of those applications in the life science market, but as you know, in 2024, we are going to make it a diagnostic, a clinical solution as well. In the first half of 2024, this platform will be FDA and IVDR approved. And in the second half of the year, we are planning to launch our first assay regulated for onco-hematology application, BCR-ABL. So as we have said since the beginning of the launch of that solution, we believe that we have the team dedicated the solution to take the #1 position in this market.

Aisyah Noor: Okay. I can ask my question now, if that’s okay. If you could talk a little bit about China and help us unpack the drivers of the weakness there. My understanding was you had a softer comp in Q4 2022 because of the COVID lockdowns. And from what your peers are saying this quarter, it sounds like a lot of the weakness is down to the Life Sciences market, which I believe is about half your China business. So could you clarify whether the China Diagnostics business is also in decline in the quarter? Just trying to understand the market dynamics within the different customer segments. And I’ll leave it there first.

Thierry Bernard: Thank you for your questions. First of all, just to highlight, our Life Science business in China is more than half of our activities for this market. And it is true that the Life Science sector in China are still not as bounce back from the COVID period. At the same time, we have constantly said that China is such a large market that it cannot be ignored. It is a specific market as well, where you need to localize your activities, if you want to continue to be selected in many tenders, where the market is also sometimes affected by price constraints, it’s what we call the VBP policy. In this regard, we have always said consistently since 2022, that the market will come back very progressively, and we were not expecting a return to growth at least before the end of ’24.

We believe that we are very well equipped to take position in this market for 3 reasons. First of all, the premium brand of QIAGEN for the top tier of the labs in China. Second, because to localize our product, we have a research development and manufacturing operation site. And third, and this is probably also very differentiated compared to competition because we have a second brand also in China, fully owned by QIAGEN, but operationally in China independent from our Qiagen activities. They have their own management, they’re all sales force, and those are products developed in China, manufactured in China and sold to Chinese customers. So with those 3 assets, we believe that, as I said before, we can take position, but at the same time, we always insisted that if pre-COVID we were expecting a normal 10% growth year after year from the Chinese market.

Post COVID progressively, we would expect a mid-single-digit growth. This will not come before 2025.

Aisyah Noor: Understood. And then the second question was just on M&A and your appetite to deploy capital from here given the recent share buyback program. Obviously, M&A activity among your peers has also picked up in the recent quarter. And then just quickly, if you could give us a contribution from Verogen in 2023, just to help us out with our models. Thanks so much.

Thierry Bernard: So on M&A, we confirm our traditional strategy. You see that you know that we have a rich history essentially, especially of bolt-on acquisition. We have always said that we don’t want to do M&A for the sake of M&A. We want to do M&A, not to spread the company’s fame again. We are constantly working, looking at opportunities that fit in our current portfolio and especially would reinforce our pillars of growth. So it’s a very focused M&A strategy. We have also said many times that we are looking at opportunities that could be during a short period of time, dilutive to our P&L, but should be in a very visible time frame, accretive. We always said that we give it normally around 2 years before becoming accretive.

And so we continue to clearly look at opportunities. We also said that given the strength of our balance sheet, we would or we could also be looking at stronger or bigger than just bolt-on acquisition. So this is a work in progress. Once again, what you have to keep in mind, it will have to be very much fitting into our existing portfolio and existing strategy. As regard to Verogen, we were expecting a contribution of around $20 million for the year 2023, and this is where we landed.

Aisyah Noor: Thanks so much.

Operator: Our next question comes from Doug Schenkel of Wolfe Research. Please go ahead.

Douglas Schenkel: Hi, good morning. Good afternoon, everyone. Thanks for sharing so much on your guidance philosophy for the year. I know there’s been a couple of questions on this and pacing. I want to take a different angle. So it’s an uncertain time to say the least, and you would have been an outlier if you guided more aggressively in Q1. So to me, while the Q1 guides lower than what we see in consensus models. I think the good thing is on the surface, it seems pretty derisked factoring in comments that you’ve made on OEM headwinds, China dynamics and how pharma growth is expected to pace in an election year. I guess my question is, where could we be wrong? What’s the biggest risk to Q1 as we sit here today? And then looking past Q1, if you don’t meet or even beat Q1 expectations, does the rest of the year start to look aspirational because it is really back-end loaded in terms of how you guided relative to the norm.

Again, I get it. But again, I wanted to see what the risk is to Q1, if any, and then get your take on what we need to see beyond a strong Q1 to have more confidence in the outlook for the year in terms of you meeting or have been beating expectations.

Thierry Bernard: I think — thanks, Derek. I think Ron and I can take — Doug I’m sorry, I can take that question. In terms of risk for Q1. Honestly, I don’t see a specific portfolio risk for Q1. The risk that I would highlight, and it’s not just impacting QIAGEN, if that happened, is the overall economic situation. Again, let’s not forget that half of the world is moving into election this year, that we believe that labs are still a bit slow to building up again their purchasing capacity. So this is for me the main challenge. Roland, in his explanation on 2024 guidance clearly also disclosed that indeed, we have an acceleration, especially between H1 and H2, clearly. Missing Q1 obviously is not our objective now. We want to continue to execute, but even if Q1 would a bit slow, I wouldn’t say necessarily that it would question the full year.

It would be far too early. Because once again, you see a logic sequential quarter-by-quarter acceleration of our performance. And my last rational argument would also be that do not forget that most of our new launches or expected extra contribution to our performance 2023 is coming in H2. We plan to have GI for QIAstat in the U.S. starting in H2. We plan to have meningitis in the U.S. for QIAstat in Q4 of the year. And we plan to have the real impact of our QIAcuity clinical diagnostic also in H2. Those are my assumption. But Roland, please.

Roland Sackers: Just a few additions and welcome back. As I said before, I also looked a bit backwards more or less a year’s pre-COVID because they are probably good indications to what we have seen before, right. And the revenue/profitability share H1, H2 for ’24 is actually in the same way as we have seen more or less for the year ’16, this ’19. So I would say, it’s quite normal in terms of ramp for the year. Second and I do think that is important as well. Again, I would not — I would rather turn it around what you said before. It is — you can now argue it’s a whamp [ph] I would rather say we expect rather back to normal in the second part of the year. So the off is rather in the first half of the year, the normal if you compare it also to the full year 2013 or even to the second half of 2023, that is what we expect to happen in the second part of the year. .

Douglas Schenkel: Thank you very much.

Operator: The next question comes from Falko Friedrichs of Deutsche Bank. Please go ahead.

Falko Friedrichs: Thank you. Good afternoon. My question is on QIAstat-Dx please, which was a little bit slower in Q4 than what we used to from this platform. Can you speak a bit about the dynamics in the fourth quarter also from a regional perspective? And outside of the test menu expansion that you’ve just referenced, what makes you confident that 2024 will be another step forward for the platform? Thank you.

Thierry Bernard: Thank you, Falko. First of all, you see when you ask about the geographic, we have to be very clear. Because of the delay of GI registration in the U.S., most of the growth currently for QIAstat is coming from Europe, from also Middle East and Asia Pacific. Those are the 3 contributions mainly to QIAstat. At the same time, it’s quite humbling to see that with one panel respiratory in the U.S., we continue to place system and take market against competition, which shows the strength of the platform. So — why are we confident? First, because we do expect, as I said before, GI and meningitis to come in the U.S. in 2024. And if by the end of ’24, you have the 3 normal, I would say, or traditional panel for syndromic testing available in the U.S., you completely changed the dynamic of growth of QIAstat in that kit market.

And I remind you that North America is still the first market in volume for syndromic testing. Second, because we have also improved our high-throughput QIAstat solution, the system that we call QIAstat rise, and we are relaunching it in 2024. In Europe, but also in the U.S. So long story short. As we have said on our last Investor Day, December the 8, 2020, QIAstat is a solution with a double-digit growth profile, definitely, and we are moving to take the second position on that market. If I would have told you we would be #1 on syndromic, it would be purely aspirational, but positioning QIAstat to really become the #2 in that market is the objective, and this is the objective we are going to achieve.

Falko Friedrichs: Okay. Thank you.

Operator: And we take our final question from Matt Sykes with Goldman Sachs. Please go ahead.

Matthew Sykes: Good morning. Thanks for taking my questions. Just one for me. Just can I appreciate the capital equipment environment you guys outlined in relation to the guidance in Q1 and ’24. But maybe just on the level of recurring revenue that you have and a lot of that is expressed in Sample Technologies. Could you maybe just give us a little bit more color on the cadence and your view on Sample Technologies over the course of the year, you obviously gave a full year guide for that business, but I would just love to understand how the cadence of that business is going to do over the course of the year, particularly in Q1 and then the back half of this year.

Thierry Bernard: I think as we described for the rest of the business, we expect a sequential acceleration here as well. Taken if you especially consider the purely non-COVID part of that Sample tech business, we will be completely aligned with the guidance once again that we gave on December the 8, 2040 [ph] portfolio, which is between low to mid-single digit. We were very close or slightly above mid in 2023. We expect to be slightly lower this year, but still in that guidance of mid to — of low to mid-single digits. Third, Sample tech is definitely the portfolio where, in addition to our current leadership, we want to continue to be on the attack. And what I mean by this is that not only are we the only company, which has systematically upgraded its instrument for the last 3 years, QIAcube becoming QIAcube Connect.

EZ1 becoming EZ2, every time with new features. As we said today, again, we will launch an upgraded version of QIAsymphony, our flashing [ph] platform by the end of 2025. And we are also planning new development in Sample tech automation that we will probably disclose during our Investor Day on June 17.

Matthew Sykes: Thank you.

End of Q&A:

John Gilardi: Thank you, Thierry. And with that, I’d like to end this call. If you have any questions or comments, please don’t hesitate to reach out to Phoebe and me, and we’re always available to help you. Bye-bye.

Operator: Ladies and gentlemen, this concludes the conference call. Thank you for joining, and have a pleasant day.